Clinical trial
Treatment for Elderly Patients With High Risk Breast Cancer
NCT00117910 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00117910 |
|---|---|
| Title | Treatment for Elderly Patients With High Risk Breast Cancer |
| Official title | An Open Label, Randomised, Multicentre Study of Pegfilgrastim in Primary Versus Secondary Prophylaxis of Neutropenia as an Adjunct to Chemotherapy in Elderly Subjects With High Risk Breast Cancer. |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | pegfilgrastim |
| Start date | Oct 1, 2002 |
| Completion | May 1, 2004 |
| First posted | Jul 11, 2005 |
| Last update posted | May 16, 2008 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: